Effects of L-arginine on fibroblast growth factor 2-induced angiogenesis in a model of endothelial dysfunction

Circulation

Volumn 112, Issue 9 SUPPL., 2005, Pages

  Voisine, Pierre ^a,c   Li, Jian ^a   Bianchi, Cesario ^a   Khan, Tanveer A ^a   Ruel, Marc ^b   Xu, Shu Hua ^a   Feng, Jun ^a   Rosinberg, Audrey ^a   Malik, Tamer ^a   Nakai, Yasunari ^a   Sellke, Frank W ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^c LAVAL UNIVERSITY   (Canada)

Author keywords

Angiogenesis; Endothelium; Growth substances; Nitric oxide

Indexed keywords

ARGININE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 1; INDUCIBLE NITRIC OXIDE SYNTHASE; NITRIC OXIDE; SYNDECAN 4;

ADOLESCENT; ANGIOGENESIS; ANIMAL MODEL; ANIMAL TISSUE; ARTERY ENDOTHELIUM; ARTICLE; BLOOD VESSEL REACTIVITY; CELL DENSITY; CHOLESTEROL DIET; CONTROLLED STUDY; CORONARY ARTERY CIRCUMFLEX BRANCH; CORONARY ARTERY DISEASE; DIET SUPPLEMENTATION; DRUG EFFECT; DRUG IMPLANT; ENDOTHELIUM CELL; HEART MUSCLE; HEART MUSCLE PERFUSION; HEART PACING; HYPERCHOLESTEROLEMIA; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; INTRAMYOCARDIAL DRUG ADMNISTRATION; LEFT ANTERIOR DESCENDING CORONARY ARTERY; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONTENT; SWINE; VASCULAR ENDOTHELIAL DYSFUNCTION;

ANGIOGENESIS INDUCING AGENTS; ANIMALS; ARGININE; ARTERIOLES; CORONARY ARTERIOSCLEROSIS; CORONARY CIRCULATION; DIET, ATHEROGENIC; DRUG IMPLANTS; DRUG SYNERGISM; ENDOTHELIUM, VASCULAR; FIBROBLAST GROWTH FACTOR 2; MEMBRANE GLYCOPROTEINS; MICROCIRCULATION; MODELS, ANIMAL; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; NITRIC OXIDE SYNTHASE TYPE III; PROTEOGLYCANS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; SWINE; SWINE, MINIATURE; SYNDECAN-4;

EID: 24644500665     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.104.526350     Document Type: Article

References (23)

1. Simons M, Bonow RO, Chronos NA, Cohen DJ, Giordano FJ, Hammond HK, Laham RJ, Li W, Pike M, Sellke FW, Stegmann TJ, Udelson JE, Rosengart TK. Clinical trials in coronary angiogenesis: issues, problems, consensus: an expert panel summary. Circulation. 2000;102:E73-E86.
2. Henry TD, Annex BH, McKendall GR, Azrin MA, Lopez JJ, Giordano FJ, Shah PK, Willerson TJ, Benza RL, Berman DS, Gibson CM, Bajamonde A, Rundle AC, Fine J, McCluskey ER; VIVA Investigators. The VIVA trial: vascular endothelial growth factor in ischemia for vascular angiogenesis. Circulation. 2003;107:1359-1365.
3. Laham RJ, Sellke FW, Edelman ER, Pearlman JD, Ware JA, Brown DL, Gold JP, Simons M. Local perivascular delivery of basic fibroblast growth factor in patients undergoing coronary bypass surgery: results of a phase I randomized, double-blind, placebo-controlled trial. Circulation. 1999;100:1865-1871.
4. Ruel M, Laham RJ, Nieman D, Sellke FW, Parker JA. Late nuclear perfusion imaging follow-up after perivascular implantation of FGF-2. J Thorac Cardiovasc Surg. 2002;124:28-39.
5. Sellke FW, Wang SY, Stamler A, Lopez JJ, Li J, Simons M. Enhanced microvascular relaxations to VEGF and bFGF in chronically ischemic porcine myocardium. Am J Physiol. 1996;271:H713-H720.
6. Arnal JF, Yamin J, Dockery S, Harrison DG. Regulation of endothelial nitric oxide synthase mRNA, protein, and activity during cell growth. Am J Physiol. 1994;267:C1381-C1388.
7. Murohara T, Witzenbichler B, Spyridopoulos I, Asahara T, Ding B, Sullivan A, Losordo DW, Isner JM. Role of endothelial nitric oxide synthase in endothelial cell migration. Arterioscler Thromb Vasc Biol. 1999;19:1156-1161.
8. Sieber CC, Sumanovski LT, Stumm M, van der Kooij M, Battegay E. In vivo angiogenesis in normal and portal hypertensive rats: role of basic fibroblast growth factor and nitric oxide. J Hepatol. 2001;34:644-650.
9. Ma L, Wallace JL. Endothelial nitric oxide synthase modulates gastric ulcer healing in rats. Am J Physiol gastrointest Liver Physiol. 2000;279: G341-G346.
10. Ruel M, Wu GF, Khan TA, Voisine P, Bianchi C, Li J, Li J, Laham RJ, Sellke FW. Inhibition of the cardiac angiogenic response to surgical FGF-2 therapy in a swine endothelial dysfunction model. Circulation. 2003;108(suppl II):II-335-II-340.
11. Jang JJ, Ho HK, Kwan HH, Fajardo LF, Cooke JP. Angiogenesis is impaired by hypercholesterolemia: role of asymmetric dimethylarginine. Circulation. 2000;102:1414-1419.
12. Quyyumi AA, Dakak N, Diodati JG, Gilligan DM, Panza JA, Cannon RO. Effect of L-arginine on human coronary endothelium-dependent and physiologic vasodilation. J Am Coll Cardiol. 1997;30:1220-1227.
13. Lerman A, Burnett JC, Higano ST, McKinley LJ, Holmes DR. Long-term L-arginine supplementation improves small-vessel coronary endothelial function in humans. Circulation. 1998;97:2123-2128.
14. Tofukuji M, Metais C, Li J, Franklin A, Simons M, Sellke FW. Myocardial VEGF expression after cardiopulmonary bypass and cardioplegia. Circulation. 1998;98(suppl II):II-242-II-246.
15. Sellke FW, Tofukuji M, Laham RJ, Li J, Hariawala MD, Bunting S, Simons M. Comparison of VEGF delivery techniques on collateral-dependent microvascular reactivity. Microvasc Res. 1998;55:175-178.
16. Ruel M, Sellke FW, Bianchi C, Khan TA, Faro R, Zhang JP, Cohn WE. Endogenous myocardial angiogenesis and revascularization using a gastric submucosal patch. Ann Thorac Surg. 2003;75:1443-1449.
17. Voisine P, Bianchi C, Ruel M, Malik T, Rosinberg A, Feng J, Khan TA, Xu SH, Sandmeyer J, Laham RJ, Sellke FW. Inhibition of the cardiac angiogenic response to exogenous vascular endothelial growth factor (VEGF) therapy in a porcine model of endothelial dysfunction. Surgery. 2004;136:407-415.
18. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res. 2000;87:840-844.
19. Vallance P, Leone A, Calver A, Collier J, Moncada S. Endogenous dimethylarginine as an inhibitor of nitric oxide synthesis. J Cardiovasc Pharmacol. 1992;20(suppl 12):S60-S62.
20. Boger RH, Bode-Boger SM, Szuba A, Tsao PS, Chan JR, Tangphao O, Blaschke TF, Cooke JP. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation. 1998;98:1842-1847.
21. Akiba Y, Nakamura M, Oda M, Kimura H, Miura S, Tsuchiya M, Ishii H. Basic fibroblast growth factor increases constitutive nitric oxide synthase during healing of rat gastric ulcers. J Clin Gastroenterol. 1997;25(suppl 1):S122-S128.
22. Li J, Parovian C, Li J, Hampton TG, Metais C, Tkachenko E, Sellke FW, Simons M. Modulation of microvascular signaling by heparan sulfate matrix: studies in syndecan-4 transgenic mice. Microvasc Res. 2002;64:38-46.
23. Voisine P, Bianchi C, Khan TA, Ruel M, Xu SH, Feng J, Li J, Malik T, Rosinberg A, Sellke FW. Normalization of coronary microvascular reactivity and improvement in myocardial perfusion by surgical VEGF therapy combined with Oral supplementation of L-arginine in a porcine model of endothelial dysfunction. J Thorac Cardiovasc Surg. 2005;129:1414-1420.